Last reviewed · How we verify
NCT06694324
First-line Treatment of Advanced/unresectable DDLPS
Phase 2 trial testing Liposomal Doxorubicin (Doxil) in Dedifferentiated Liposarcoma in 49 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 1 December 2024 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Liposomal Doxorubicin (Doxil) — full drug profile →
- Apatinib (Apatinib) — full drug profile →
- Camrelizumab — full drug profile →
Conditions studied
- Dedifferentiated Liposarcoma — all drugs for Dedifferentiated Liposarcoma →
- Soft Tissue Sarcoma (STS) — all drugs for Soft Tissue Sarcoma (STS) →
Sponsor
Fudan University
Who can join
Adults 18 to 75, any sex, with Dedifferentiated Liposarcoma or Soft Tissue Sarcoma (STS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06694324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liposomal Doxorubicin (Doxil)
Trials testing the same drug.
- NCT05210374 — Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas · Phase 1 · recruiting
Other recruiting trials for Dedifferentiated Liposarcoma
Currently open trials in the same condition.
- NCT06975293 — STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants · Phase 1, PHASE2 · recruiting
- NCT06843967 — A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma · Phase 1, PHASE2 · recruiting
- NCT06389799 — A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) · Phase 2 · recruiting
- NCT05886634 — A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma · Phase 2 · active not recruiting
- NCT03307616 — Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferen · Phase 2 · active not recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06694324 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06694324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing